Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Common Equity: 2022-2025

Historic Common Equity for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -$82.3 million.

  • Gossamer Bio's Common Equity fell 252.09% to -$82.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.3 million, marking a year-over-year decrease of 252.09%. This contributed to the annual value of $29.5 million for FY2024, which is 53.02% down from last year.
  • According to the latest figures from Q3 2025, Gossamer Bio's Common Equity is -$82.3 million, which was down 78.57% from -$46.1 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Common Equity ranged from a high of $104.6 million in Q3 2023 and a low of -$82.3 million during Q3 2025.
  • Moreover, its 3-year median value for Common Equity was $26.7 million (2024), whereas its average is $12.1 million.
  • Examining YoY changes over the last 5 years, Gossamer Bio's Common Equity showed a top increase of 419.74% in 2023 and a maximum decrease of 281.51% in 2023.
  • Over the past 4 years, Gossamer Bio's Common Equity (Quarterly) stood at $12.1 million in 2022, then spiked by 419.74% to $62.8 million in 2023, then slumped by 53.02% to $29.5 million in 2024, then crashed by 252.09% to -$82.3 million in 2025.
  • Its Common Equity stands at -$82.3 million for Q3 2025, versus -$46.1 million for Q2 2025 and -$6.2 million for Q1 2025.